Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WARRIOR: First-Line Osimertinib in Advanced EGFR-Mutated NSCLC
NCT03969823Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- May 2019
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Seoul National University Hospital. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03969823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969823.